P427: Development of an index that predicts escalation of therapy at an outpatient appointment in patients with known ulcerative colitis (UC)ECCO '18 Vienna
2018
P428: Pharmacist-led proactive therapeutic drug monitoring with infliximab (PROXIMO): Utility of and cost-saving associated with the use of a rapid assay for assessing drug levelECCO '18 Vienna
2018
P429: Robotic-assisted vs. laparoscopic proctectomy for inflammatory bowel disease: Results of the case-match comparison in single institutionECCO '18 Vienna
2018
P430: Distinct faecal bile acid profiles are associated with sustained remission following exclusive enteral nutrition (EEN) induction therapy in paediatric Crohn's diseaseECCO '18 Vienna
2018
P431: Golimumab dried blood spot analysis (GOUDA): A prospective trial to validate golimumab concentration analysis using the dried blood spot methodologyECCO '18 Vienna
2018
P432: Does medical acceleration improve long-term outcomes in ulcerative colitis patients who are in clinical remission but have endoscopic mucosal inflammation?ECCO '18 Vienna
2018
P433: Faecal calprotectin is correlated to endoscopic disease activity at Week 16 in IBD patients on vedolizumab therapyECCO '18 Vienna
2018
P435: Effectiveness of therapeutic drug monitoring of infliximab and adalimumab in inflammatory bowel disease patients. Systematic review and meta-analysisECCO '18 Vienna
2018
P436: Ileal pouch-anal anastomosis with fluorescence angiography: Initial experience and potential applicationECCO '18 Vienna
2018
P437: Higher adalimumab maintenance regimens are more effective than standard maintenance doses in Crohn’s disease patients who have failed infliximabECCO '18 Vienna
2018
P438: Reinduction with ustekinumab in Crohn’s disease patients with a loss of response to treatmentECCO '18 Vienna
2018
P439: Monitoring inflammatory Bowel disease activity in a virtual biologic clinic: The effects of proactive therapeutic drug monitoring on patient reported outcome measuresECCO '18 Vienna
2018
P440: Early changes in the pharmacokinetic profile of vedolizumab-treated patients with inflammatory bowel disease may predict response after dose optimisationECCO '18 Vienna
2018
P441: Higher education, professional occupation and upper socio-economic status is associated with lower adherence to medications in patients with inflammatory bowel diseaseECCO '18 Vienna
2018
P442: The additional value of cytapheresis therapy in patients with severe ulcerative colitis treated with oral tacrolimusECCO '18 Vienna
2018
P443: Systematic analysis of annual health resource utilisation and costs in hospitalised inflammatory bowel disease patients in SwitzerlandECCO '18 Vienna
2018
P445: Patients with active perianal fistulas have a reduced physical health compared with Crohn’s patients without perianal fistulasECCO '18 Vienna
2018